- Carfilzomib–dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leukemia and Lymphoma. 2017 Academic Article GET IT
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
The lancet oncology.
Times cited: 118
Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
Times cited: 11
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
Journal of Clinical Oncology.
Times cited: 128
IMWG consensus on maintenance therapy in multiple myeloma.
Times cited: 127